Suppr超能文献

[慢性肾脏病的铁剂治疗]

[Iron therapy in chronic kidney disease].

作者信息

Graczyk Maciej, Kohmann Anna

机构信息

Katedra i Klinika Nefrologii, Dializoterapii i Chorób Wewnętrznych WUM, Warszawa, Polska,

Katedra i Klinika Nefrologii, Dializoterapii i Chorób Wewnętrznych WUM, Warszawa, Polska.

出版信息

Wiad Lek. 2016;69(5):749-752.

Abstract

Iron deficiency is one of the main causes of anemia in patients with chronic kidney disease, and iron supplements along the erythropoietin constitute the basis of its therapy. Among hemodialysis patients a preferred method of iron supplementation is an intravenous route, but the route of administration of iron to patients with nondialysis CKD raises a lot of controversy. Treatment with oral iron is cheap, does not require vascular access, but of lower efficacy due to insufficient absorption and frequent occurrence of side effects from the gastrointestinal, with discontinuation of therapy. Intravenous iron though effective is associated with the risk of allergic reactions, oxidative stress and the risk of iron overload. Modern oral medications may constitute an alternative to intravenous iron.

摘要

缺铁是慢性肾脏病患者贫血的主要原因之一,铁补充剂与促红细胞生成素一起构成了其治疗的基础。在血液透析患者中,补铁的首选方法是静脉途径,但对于非透析慢性肾脏病患者,铁剂的给药途径存在很多争议。口服铁剂治疗价格便宜,不需要血管通路,但由于吸收不足和胃肠道副作用频繁发生,导致疗效较低,且需要中断治疗。静脉铁剂虽然有效,但与过敏反应、氧化应激和铁过载风险相关。现代口服药物可能是静脉铁剂的替代选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验